EGFRvⅢ的表达对吉非替尼作用卵巢癌SKOV3细胞敏感性的影响

Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment

摘要:

目的：探讨EGFRvⅢ的表达与卵巢癌SKOV3细胞对化疗药吉非替尼敏感性之间的关系，为临床治疗并合理选用抗肿瘤药物提供参考。方法：将质粒pcDNA4/TO-EGFRvⅢ稳定转染入SKOV3细胞，并用zeocin抗生素筛选出稳定表达EGFRvⅢ蛋白的细胞株（命名为SKOV3-EGFRvⅢ），用MTT法检测转染稳定株和原始株在吉非替尼作用下细胞的存活能力。然后，以吉非替尼分别对2株细胞建立的裸鼠异体肿瘤模型进行治疗，通过测量肿瘤体积大小评价肿瘤模型对吉非替尼的敏感性。结果：通过Western blot 鉴定，SKOV3-EGFRvⅢ稳定株建立成功；MMT法结果表明SKOV3-EGFRvⅢ细胞在吉非替尼的作用下，其死亡率低于原始细胞株，且吉非替尼对SKOV3-EGFRvⅢ细胞建立的裸鼠肿瘤模型的抑制效果明显低于原始细胞株。结论：EGFRvⅢ的过表达导致卵巢癌SKOV3细胞及其体外移植肿瘤模型对化疗药吉非替尼的敏感性减弱。

Abstract:

Objective：To determine the relationship between EGFRvⅢ expression and sensitivity of SKOV3 cell to Gefitinib and to give rational guidance to clinical medication. Methods：Plasmid pcDNA4/TO-EGFRvⅢ was stably transfected into SKOV3 cell and the cell strains stably expressing EGFRvⅢ were screened out by zeocin antibiotics and named SKOV3-EGFRvⅢ. MTT was used to assess the viability of SKOV3- EGFRvⅢ cell and SKOV3 cell treated by Gefitinib. Nude mice allograft tumor models bearing SKOV3 and SKOV-EGFRvⅢ were treated by Gefitinib. The sensitivity of the tumor model to Gefitinib was assessed by measuring the tumor size. Results：Results of Western blot indicated that SKOV3-EGFRvⅢ cell strain was successfully established. According to the results of MMT，after being treated by Gefitinib，the mortality was lower in SKOV3-EGFRvⅢ cell than in SKOV3 cell and the inhibi－tion effect of Gefitinib was less intense on tumor model carrying SKOV3-EGFRvⅢ cell than on that carrying SKOV3. Conclusion：Over expression of EGFRvⅢ in ovarian cancer SKOV3 cell results in its decreased sensitivity to Gefitinib.